This finding was independently corroborated in tumour specimens from two lorlatinib-treated patients, while an additional two ceritinib-treated patients displayed de novo loss-of-function mutations in the gene encoding neurofibromin (NF1; R1276∗ nonsense, F1593S) [112]. The gene discussed is NF1; the disease is neoplasm.